Cardisio GmbH, founded in 2016 and headquartered in Frankfurt am Main, specializes in the early detection of heart disease through its proprietary Cardisiography (CSG) method. This innovative screening procedure is designed to quickly, precisely, and non-invasively detect pathological patterns indicative of heart disease, even before symptoms appear. The company serves general practitioners and cardiologists, providing them with a reliable tool to diagnose heart conditions early, thereby enabling more effective disease prevention and treatment. Cardisio operates in the healthcare market, particularly focusing on cardiovascular diagnostics. The business model involves selling the CSG technology to medical practices and clinics, and it generates revenue through the sale of its screening devices and related services. Cardisio also collaborates with sales and distribution partners in several countries, expanding its market reach. The CSG method boasts a sensitivity rate of 90%, significantly higher than the traditional stress ECG, and is accepted by many health insurers in Germany, making it a valuable addition to medical practices.

Keywords: Cardisiography, heart disease, early detection, non-invasive, AI-enhanced, diagnostics, general practitioners, cardiologists, healthcare, Germany.